JP2024528990A5 - - Google Patents

Info

Publication number
JP2024528990A5
JP2024528990A5 JP2024506685A JP2024506685A JP2024528990A5 JP 2024528990 A5 JP2024528990 A5 JP 2024528990A5 JP 2024506685 A JP2024506685 A JP 2024506685A JP 2024506685 A JP2024506685 A JP 2024506685A JP 2024528990 A5 JP2024528990 A5 JP 2024528990A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
inclusion complex
complex formulation
formulation according
amylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528990A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/056550 external-priority patent/WO2023012552A1/en
Publication of JP2024528990A publication Critical patent/JP2024528990A/ja
Publication of JP2024528990A5 publication Critical patent/JP2024528990A5/ja
Pending legal-status Critical Current

Links

JP2024506685A 2021-08-04 2022-07-15 アナンダミドシクロデキストリン包接錯体ビヒクル Pending JP2024528990A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163229447P 2021-08-04 2021-08-04
US63/229,447 2021-08-04
PCT/IB2022/056550 WO2023012552A1 (en) 2021-08-04 2022-07-15 Anandamide cyclodextrin inclusion complex vehicles

Publications (2)

Publication Number Publication Date
JP2024528990A JP2024528990A (ja) 2024-08-01
JP2024528990A5 true JP2024528990A5 (enExample) 2025-07-01

Family

ID=85155427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506685A Pending JP2024528990A (ja) 2021-08-04 2022-07-15 アナンダミドシクロデキストリン包接錯体ビヒクル

Country Status (9)

Country Link
US (1) US20250205181A1 (enExample)
EP (1) EP4380556A4 (enExample)
JP (1) JP2024528990A (enExample)
KR (1) KR20240050356A (enExample)
CN (1) CN118043040A (enExample)
AU (1) AU2022323827A1 (enExample)
CA (1) CA3227102A1 (enExample)
IL (1) IL310613A (enExample)
WO (1) WO2023012552A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024199007A1 (zh) * 2023-03-28 2024-10-03 南京纽邦生物科技有限公司 花生四烯酸乙醇胺组合物
WO2025229618A1 (en) * 2024-05-02 2025-11-06 Czap Research And Development, Llc Blood glucose control with enzymatic cyclodextrin inclusion complex formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001558A1 (en) * 1994-07-11 1996-01-25 Pate David W Anandamide analogue compositions and method of treating intraocular hypertention using same
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20170224841A1 (en) * 2016-02-04 2017-08-10 Czap Reseach And Development, Llc Controlled-release and stratified cyclodextrin inclusion complex vehicles
JP7758353B2 (ja) * 2020-03-23 2025-10-22 クザップ リサーチ アンド デベロップメント エルエルシー 経口テルペンシクロデキストリン包接体ビヒクル

Similar Documents

Publication Publication Date Title
Sharma et al. Antibacterial PEG-chitosan hydrogels for controlled antibiotic/protein delivery
US12377055B2 (en) Dissolvable gel-forming film for delivery of active agents
US11969517B2 (en) Compositions and methods for macrophage conversion
JP2019131596A5 (enExample)
Liu et al. In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin
Labelle et al. Structure‐functions relationship of modified starches for pharmaceutical and biomedical applications
Linden et al. Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen
Lumholdt et al. In vitro investigations of α-amylase mediated hydrolysis of cyclodextrins in the presence of ibuprofen, flurbiprofen, or benzo [a] pyrene
Feng et al. Genipin crosslinked ethyl cellulose–chitosan complex microspheres for anti-tuberculosis delivery
JP2016535790A (ja) 医薬製剤ならびにその製造および使用
JP2005508981A5 (enExample)
JP2023519232A5 (enExample)
RU2013132210A (ru) Новая фармацевтическая композиция, включающая нпвс и циклодекстрин
Liang et al. Injectable DNA hydrogels with intrinsic antioxidant and anti-inflammatory functions for effectively healing bacteria-infected diabetic wounds
EA009714B1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
Mirshafiey et al. Sodium alginate as a novel therapeutic option in experimental colitis
JP5464750B2 (ja) 抗菌性組成物
BR112022019223A2 (pt) Formulação de complexo de inclusão em ciclodextrina (cd), complexo de inclusão em ciclodextrina (cd), uso da formulação de complexo de inclusão em ciclodextrina (cd), uso de um veículo de entrega de um complexo de inclusão em ciclodextrina, método para o tratamento oral de uma disfunção, método para o tratamento oral de um humano, uso da composição, composição e método de tratamento de um transtorno das vias aéreas
TW201737938A (zh) 慢性傷口之清創方法
Jithendra et al. Bioassessment of the inflammatory response of macrophages to collagen-chitosan scaffold blended with Aloe vera
Mašková et al. Design and evaluation of composite films for in situ synthesis and antibacterial activity of allicin vapour
Patil et al. Advances and challenges in serratiopeptidase topical formulation
Sanchez Armengol et al. Generations of chitosan: The progress in drug delivery
CN103619339A (zh) 含有利马前列素和β-环糊精的片剂
EP0542977A1 (fr) Composition orale a base d'un materiau antibiotique et d'une argile